Post-Revascularization Readmission Trends for Peripheral Arterial Disease

Share this content:
Readmission for PAH had a median cost of $11,013.
Readmission for PAH had a median cost of $11,013.

HealthDay News — For patients with peripheral arterial disease who are discharged following peripheral arterial revascularization, 17.6% have 30-day nonelective readmission, according to a study published online in the Annals of Internal Medicine.

Eric A. Secemsky, MD, from the Beth Israel Deaconess Medical Center in Boston, and colleagues examined readmissions after peripheral arterial revascularization for peripheral arterial disease in a retrospective cohort study. Data were included for 61,969 unweighted hospitalizations of patients with peripheral arterial disease who were discharged from 1085 US acute care hospitals.

The researchers found that the 30-day elective readmission rate was 17.6% among patients discharged alive after peripheral arterial revascularization. The most common causes of readmission were procedural complications, sepsis, and complications due to diabetes mellitus (28.0%, 8.3%, and 7.5%). Twenty-one percent of rehospitalized patients underwent a subsequent peripheral arterial revascularization or lower extremity amputation and 4.6% died. Readmission had a median cost of $11,013. There was variation in the 30-day risk-standardized readmission rates between hospitals, from 10.0% to 27.3%.

"More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arterial revascularization have unplanned readmission within 30 days, with high associated mortality risks and costs," the authors write.

Several authors disclosed financial ties to the pharmaceutical and health care industries.

Reference

Secemsky EA, Schermerhorn M, Carroll BJ, et al. Readmissions after revascularization procedures for peripheral arterial disease: a nationwide cohort study [published online December 5, 2017]. Ann Intern Med. doi:10.7326/M17-1058

You must be a registered member of The Cardiology Advisor to post a comment.

Sign Up for Free e-Newsletters